Document is current
Any future updates will be listed below
-
Authors
Karwacki-Neisius, Violetta https://orcid.org/0009-0006-6273-9814
Jang, Ahram
Cukuroglu, Engin
Tai, Albert https://orcid.org/0000-0001-7771-0850
Jiao, Alan
Predes, Danilo https://orcid.org/0000-0003-1864-0324
Yoon, Joon
Brookes, Emily https://orcid.org/0000-0003-2175-4349
Chen, Jiekai https://orcid.org/0000-0001-5168-7074
Iberg, Aimee
Halbritter, Florian https://orcid.org/0000-0003-2452-4784
Õunap, Katrin https://orcid.org/0000-0002-4594-6364
Gecz, Jozef https://orcid.org/0000-0002-7884-6861
Schlaeger, Thorsten M. https://orcid.org/0000-0002-1599-9908
Ho Sui, Shannan https://orcid.org/0000-0002-6191-4709
Göke, Jonathan https://orcid.org/0000-0002-0825-4991
He, Xi https://orcid.org/0000-0002-8093-7981
Lehtinen, Maria K. https://orcid.org/0000-0002-7243-2967
Pomeroy, Scott L.
Shi, Yang https://orcid.org/0000-0001-9713-1709
- License Information
-
More Information
Article History
Received: 7 January 2023
Accepted: 12 January 2024
First Online: 21 February 2024
Competing interests
: Y.S. is a co-founder and board member of Alternative Bio (ABio). Y.S. is also a board member of Epigenica and a member of the Scientific Advisory Board of Epic Bio, the School of Life Sciences and Westlake Laboratory of Life Sciences and Biomedicine, Westlake University, China, and the Centre for Embryology and Healthy Development, Norway. Y.S. holds equity in Active Motif, K36 Therapeutics, Epic Bio, ABio and Epigenica. All other authors declare no competing interests.
